https://www.selleckchem.com/pr....oducts/nuciferine.ht
50, 95% CI 0.44-0.56; 0.00001), and major gastrointestinal bleeding (RR = 0.77, 95% CI 0.62-0.95; = 0.02), and a borderline significant decrease in major adverse cardiac events (RR = 0.87, 95% CI 0.75-1.00; = 0.05) in NVAF patients with diabetes. For patients with NVAF and diabetes in real-world clinical settings, DOACs showed superior efficacy and safety profile over VKAs and significantly reduced risks of stroke, ischemic stroke, SSE, myocardial infarction, major bleeding, intracranial hemorrhage, and major gastrointestinal bl
Like
Comment
Share
